BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37743107)

  • 1. Fragmented care, Commission on Cancer accreditation, and overall survival in patients receiving surgery and chemotherapy for esophageal cancer.
    Verm RA; Baker MM; Cohn T; Park S; Swanson J; Freeman R; Abdelsattar ZM
    Surgery; 2024 Mar; 175(3):618-628. PubMed ID: 37743107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragmented care in localized pancreatic cancer: Is commission on cancer accreditation associated with improved overall survival?
    Park SS; Verm RA; Abdelsattar ZM; Kramer S; Swanson J; Fernando M; Cohn T; Luchette FA; Baker MS
    Surgery; 2024 Mar; 175(3):695-703. PubMed ID: 37863686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
    Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
    J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of Use of Induction Therapy for T2N0 Esophageal Cancer.
    Rhodin KE; Raman V; Jawitz OK; Voigt SL; Farrow NE; Harpole DH; Tong BC; D'Amico TA
    Ann Thorac Surg; 2021 Feb; 111(2):440-447. PubMed ID: 32681837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer.
    Rhodin KE; Raman V; Eckhoff A; Liu A; Creasy J; Nussbaum DP; Blazer DG
    Ann Surg Oncol; 2022 Sep; 29(9):5422-5431. PubMed ID: 35723791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Center Esophagectomy Volume on Outcomes in Clinical Stage I to III Esophageal Cancer.
    Rhodin KE; Raman V; Jensen CW; Kang L; Harpole DH; D'Amico TA; Tong BC
    Ann Surg; 2023 Jul; 278(1):79-86. PubMed ID: 36040026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.
    Samson P; Puri V; Lockhart AC; Robinson C; Broderick S; Patterson GA; Meyers B; Crabtree T
    J Thorac Cardiovasc Surg; 2018 Oct; 156(4):1725-1735. PubMed ID: 30054137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consequences of Refusing Surgery for Esophageal Cancer: A National Cancer Database Analysis.
    Rahouma M; Harrison S; Kamel M; Nasar A; Lee B; Port J; Altorki N; Stiles B
    Ann Thorac Surg; 2018 Nov; 106(5):1476-1483. PubMed ID: 30055137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base.
    Naik KB; Liu Y; Goodman M; Gillespie TW; Pickens A; Force SD; Steuer CE; Owonikoko TK; Ramalingam SS; Higgins K; Beitler JJ; Shin DM; Willingham FF; El-Rayes B; Landry JC; Fernandez FG; Saba NF
    Cancer; 2017 Sep; 123(18):3476-3485. PubMed ID: 28464264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
    Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy is associated with improved survival after esophagectomy without induction therapy for node-positive adenocarcinoma.
    Speicher PJ; Englum BR; Ganapathi AM; Mulvihill MS; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
    J Thorac Oncol; 2015 Jan; 10(1):181-8. PubMed ID: 25490005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Traveling to a High-volume Center is Associated With Improved Survival for Patients With Esophageal Cancer.
    Speicher PJ; Englum BR; Ganapathi AM; Wang X; Hartwig MG; D'Amico TA; Berry MF
    Ann Surg; 2017 Apr; 265(4):743-749. PubMed ID: 28266965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of pathologic node-positive disease following initial surgery for clinical T1-2 N0 esophageal cancer: patterns of care and outcomes from the national cancer data base.
    Haque W; Verma V; Bernicker E; Butler EB; Teh BS
    Acta Oncol; 2018 Jun; 57(6):782-789. PubMed ID: 29188742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant Therapy for Node-Positive Esophageal Cancer After Induction and Surgery: A Multisite Study.
    Semenkovich TR; Subramanian M; Yan Y; Hofstetter WL; Correa AM; Cassivi SD; Inra ML; Stiles BM; Altorki NK; Chang AC; Brescia AA; Darling GE; Allison F; Broderick SR; Etchill EW; Fernandez FG; Chihara RK; Litle VR; Muñoz-Largacha JA; Kozower BD; Puri V; Meyers BF
    Ann Thorac Surg; 2019 Sep; 108(3):828-836. PubMed ID: 31229485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
    Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Esophagectomy Provide a Survival Advantage to Patients Aged 80 Years or Older? Analyzing 5066 Patients in the National Database of Hospital-based Cancer Registries in Japan.
    Motoyama S; Maeda E; Iijima K; Sato Y; Koizumi S; Wakita A; Nagaki Y; Fujita H; Yoneya T; Imai K; Terata K; Minamiya Y; Higashi T
    Ann Surg; 2022 Jul; 276(1):e16-e23. PubMed ID: 33630469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiation With Neoadjuvant Chemotherapy Does Not Improve Outcomes in Esophageal Squamous Cell Cancer.
    Miller JA; Groman A; Yendamuri S; Hennon M
    J Surg Res; 2019 Apr; 236():259-265. PubMed ID: 30694764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma.
    Rucker AJ; Raman V; Jawitz OK; Voigt SL; Harpole DH; D'Amico TA; Tong BC
    Ann Surg; 2022 Feb; 275(2):348-355. PubMed ID: 32209899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgery Is Associated With Survival Benefit in T4a Esophageal Adenocarcinoma: A National Analysis.
    Raman V; Jawitz OK; Voigt SL; Farrow NE; Yang CJ; D'Amico TA; Harpole DH
    Ann Thorac Surg; 2019 Dec; 108(6):1633-1639. PubMed ID: 31356800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.